Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
5
×
boston top stories
life sciences
national blog main
national top stories
alnylam pharmaceuticals
new york blog main
new york top stories
san diego blog main
san diego top stories
biotech
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alexion pharmaceuticals
boston
celgene
clinical trials
drug prices
hereditary transthyretin amyloidosis
patisiran
pfizer
rna interference
roche
What
drug
5
×
gene
5
×
bio
roundup
disease
fda
prices
protein
therapy
advanced
alnylam
alnylam’s
alzheimer’s
approval
approves
aren’t
bff
caught
causing
cells
companies
conference
deals
developers
devoted
dicerna
different
drugs
easl
ema
employ
europe
eye
fail
follows
form
harmful
help
hepatitis
hits
Language
unset
Current search:
gene
×
drug
×
" boston blog main "
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More